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Abstract: 
The aim of the present investigation was to develop the ciprofloxacin gastroretentive floating capsules by using hydrophilic 
rate retarding and swellable polymers. The different concentration and combination of Hydroxy Propyl Methyl Cellulose 
(HPMC) and carbopol 947P polymers influenced the release of the drug, the swellable matrix retained in the stomach by 
imbibing the CO2 gas released. The effervescence of CO2 generated by the sodium bicarbonate and citric acid added in 2.70 
- 6.0 and 2.70 - 4.0 % w/w respectively except for formulation F4&F8. Formulation F1-F8 were prepared by adding 27 – 
43.86% w/w of HPMC (F1-F4) and same % weight for carbopol swellable polymer (F5-F8). The combination of these 
polymers was used to prepare F9 & F10 formulation contained with 20.83% w/w of HPMC and carbopol polymers. 2.08 % 
w/w Sodium carbonate and 4.17% w/w of citric acid for F9 whereas F10 formulation composed of with 30.00% w/w of 
HPMC and 10.00 % w/w carbopol polymers, 04% w/w Sodium carbonate and 06% w/w of citric acid. The floating capsules 
evaluated for weight variation, content uniformity showed the acceptable results as per standards. In vitro gastric buoyancy 
was acceptable for the selected formulations, the order of drug released was as follows for the selected formulations 
F4>F10 >F9>F3>F8>F7. The optimized F9 formulation showed (70.85% drug release within 12 hours) with non –Fickian 
diffusion release pattern as per the applied release kinetic models. Further XRD studies revealed compatibility for the drug 
and polymers used in the optimized formulation F9. Thus F9 floating capsules could be a model for sustained release of the 
ciprofloxacin from the narrow absorption window in the stomach thereby achieving the maximum antibacterial activity and 
patient compliance. 
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INTRODUCTION: 
Oral route is the robust and extensively accepted, 
add up to 60 % of formulation marketed are from 
this category [1].The retention of the dosage unit in 
the stomach is desirable to achieve the 
pharmacodynamics and pharmacokinetics benefits. 
Prolonged gastric retention can be achieved by high 
density, low density, and mucoadhesive and 
swelling systems [2].  
Ciprofloxacin HCl is a broad spectrum, 
fluroquinolone antibiotics used in bone infection, 
respiratory tract, and urinary tract infections [3]. It 
has the absorption window in the stomach and 
proximal part at the pylorus region [4]. The matrix 
tablets have the drawback of lower absorption for 
tablet passes down to GIT [5]. 
Therefore the aim of this study will be retaining the 
drug unit at the stomach region to enhance the 
absorption from sustained release floating capsule 
with prolonged duration of antibiotic action. The 
plasma fluctuation could be decreased by the 
controlled release of drug with the use of 
hydrophilic rate retarding polymer (HPMC).    
Controlled release of the ciprofloxacin HCl could 
be achieved by formulating the floating capsules 
with hydrophilic rate retarding and swellable 
(HPMC & Carbopol) polymers. The effervescence 
of CO2 will be generated by the citric acid and 
sodium bicarbonate added in the formulation, this 
gas helps the dosage form to float in the stomach 
by imbibing in the swelling matrix. The prepared 
capsule will be evaluated for gastric retention 
(Buoyancy study), dissolution and release kinetics.  
Globally there are about 375 identified generic 
infectious diseases of which 215 are proliferating to 
Saudi Arabia [6]. Therefore the floating capsules of 
ciprofloxacin HCl could be an efficient drug 
delivery for the effective treatment of drug, thereby 
reducing the cost of therapy and increase the 
patient compliance.    
 
METHODOLOGY 
Preparation of oral floating capsules 
Weighted amount of ciprofloxacin HCl (250mg) is 
blended with hydrophilic rate retarding and 
swellable (HPMC & Carbopol) polymers in the 
different % weight ratios and combinations to get 
10 formulations in three different concentrations of 
each polymers and its blend as showed in table -01. 
This blend was then mixed with gas generating 
effervescent agents; anhydrous citric acid and 
sodium bicarbonate to get the homogeneous 
mixture of all the ingredients. The powder material 
was filled in the hard gelatin capsule of # 00 size 
[7]. 
 
Evaluation of floating capsules  
After filling the capsules with the above mentioned 
ingredients they were evaluated for the following 
parameters. 
Appearance and capsules locking 
The general appearance detected viz morphological 
features; size shape, colour. As the content of the 
capsule was filled with hand therefore after filling 
the capsules were evaluated for to ensure the cap is 
fixed with the base of the capsule and locked in the 
ring. 
Uniformity of weight   
Uniformity of dosage units’ weight was performed 
as per USP the United States Pharmacopeial 
Convention report. Capsules were randomly 
selected from the batch and weighed on electronic 
balance the result was correlated with the 
theoretical weight of individual capsule [8]. The 
results showed in the table no 2.  
Uniformity of content  
Accurately weight about 100 mg of the formulation 
content and dissolved in 0.1 N HCl and volume 
was made up to 100 ml. The solution was filtered 
by Whattman filter paper # 41. The concentration 
was tested in UV Spectrophotometer (Jasco-V-750 
UV-Visible/NIR) at 277 nm against the blank of  
0.1 N HCl [9,10].  The results showed in the table 
no 2.  
In-vitro Buoyancy study  
Formulated capsules were subjected to floating 
study by placing the capsule in the USP Dissolution 
test apparatus II method with a paddle rotation of 
50 Rpm and 0.1N HCl used as medium. The 
duration of time was assessed for all the 
formulation and based on the maximum floating 
time they were selected for further evaluated for 
release & kinetics studies [11]. The results showed 
in the table no 3 and figured in Fig 01.  
In-vitro dissolution studies  
In-vitro dissolution studies were performed in 
dissolution test apparatus II (Paddle). The 
dissolution medium was 900 ml 0.1 N HCl the test 
was performed at 37°C the rotation of paddle was 
75 Rpm as per the USP specifications. The samples 
were withdrawn at predetermined time intervals of 
0.0, 0.5, 01, 02, 03, 04 and 12 hours. 5 ml sample 
was withdrawn and same amount is replaced with 
dissolution medium to maintain the sink conditions 
[12]. The aliquots were then assessed for 
concentration of ciprofloxacin, diluted when 
required with 0.1 N HCl and analysed in UV 
Spectrophotometer at 277 nm λ max. The 
dissolution time profiles graphs for all formulations 
are figured in Fig 02. 
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Table 1: Formulation of Ciprofloxacin floating capsule 
 
In-vitro drug release kinetics  
The release profiles of all the 6 formulations were exploited in the kinetics models viz; Zero order, First order, 
Higuchi and Korsmeyer-Peppas models by using MS-Excel software integrated with the respective equations of 
these models [13].    
The mechanism of release was determined by R2 value from each of the model for all the 6 formulations. The 
results showed in the table no 4. 
Drug-polymer compatibility studies 
XRD Studies was done by taking the diffractograms of the ciprofloxacin, polymers individually and for the 
optimized formulation F9. Diffractograms are pictured in Fig 03. 
 
RESULTS: 
 
Table 2: Uniformity of weight and content for Ciprofloxacin floating capsule 
 
Formulation code Calculated  total weight 
(mg) 
Accepted variation standards as 
per USP % weight range*  
Uniformity of 
content 
% 
F1 370 3.21 98.99 
F2 435 1.25 99.26 
F3 500 2.33 99.15 
F4 570 4.25 99.48 
F5 370 3.45 98.47 
F6 435 2.54 99.77 
F7 500 2.14 99.74 
F8 570 2.24 101.0 
F9 480 4.25 99.92 
F10 500 3.45 99.66 
*All formulation showed less than 5% weight variation 
 
Table 3: In-vitro Buoyancy study 
  
Formulation code Total floating time (Hours) Integrity of polymer matrix  
F1 ≤24 - 
F2 <24 - 
F3 ≥24 - 
F4 ≥24 - 
F5 ≤1 - 
F6 <1 - 
F7 ≥3.1 - 
F8 ≥4.9 - 
F9 ≥12 + 
F10 >24 + 
 
 
 
 
 
 
INGRIDIENT 
(mg) 
FORMULATIONS CODE 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Ciprofloxacin HCL 250 250 250 250 250 250 250 250 250 250 
HPMC K4M 100 150 200 250 - - - - 100 150 
Carbopol - - - - 100 150 200 250 100 50 
Sodium Carbonate 10 20 30 - 10 20 30 - 10 20 
Citric Acid 10 15 20 - 10 15 20 - 20 30 
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Fig 01: In-vitro Buoyancy study of floating capsules 
 
 
Fig 02: In-vitro dissolution profiles of floating capsules 
 
Table 4: Release kinetics models of ciprofloxacin floating capsules  
 
Kinetics  Models 
FORMULATION CODE 
F3 F4 F7 F8 F9 F10 
Zero Order 0.966 0.979 0.966 0.987 0.990 0.980 
First Order 0.845 0.939 0.812 0.904 0.972 0.932 
Higuchi matrix 0.960 0.979 0.966 0.987 0.990 0.980 
Korseneyer - Peppas 0.961 0.996 0.995 0.913 0.982 0.990 
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a: Ciprfloxacin HCl 
 
b: Optimized formulation F9 
Fig 03:XRD diffractograms of pure drug (a) and formulation (b) 
 
DISCUSSION: 
Appearance and capsules locking 
The formulation were prepared as per the standard 
procedure by following the cGMP and passed this 
test. 
Uniformity of weight   
The weight variation was found to be within the 
USP limits of < 25 % weight for the formulated 
capsules.  
Uniformity of content  
All the formulation showed the % content 
uniformity as per the USP standards and the % 
drug was found to be within the permissible limits 
of +/- 5%. 
In-vitro Buoyancy study  
The total floating time was from 1 to 24 hours. It 
was observed that the concentration of gas 
generating agents plays an important role in the 
floating time formulation F3 & F10 contains 
sodium bicarbonate and citric acid in 30:20 % w/w 
ratios has total floating time ≥24. Formulation F4 
& F8 without gas generating agents has ≥24hr and 
≥4.9 hr respectively the reason could be F4 
contained 43.86% HPMC K4M and F8 composed 
of same % of carbopol but float only ≥4.9 hours. 
HPMC K4M in aqueous environment lower the 
density of capsule units and float for prolong time.   
The gas generating agents integrated with polymer 
matrix once reached the gastric pH starts releasing 
the effervescent due to CO2 generations which 
could forms bubbles in the matrix and helps to float 
the dosage unit.    
In-vitro dissolution studies  
From the Figure -2 it was observed that the 
Ciprfloxacin floating capsules released 20% of the 
drug within 1 hour except for the formulation F4 & 
F10. 
After 4 hours all formulation released 50% of the 
drug except F4 formulation consisting of 43.86: 
43.86 % w/w Drug: HPMC K4M polymer ratio. 
The dissolution time profile plot revealed that the 
F3& F4 formulation consisting of 50:40 ; 43.86: 
43.86 % w/w Drug: HPMC K4M polymer ratio 
released the drug sustained manner for more than 
12 hours. Whereas F7 & F8 formulation prepared 
by carbopol in the same ratio released the more 
than 85% of drug within 12 hours. 
The formulation F9& F10 prepared with 
combination of Drug : HPMC K4M : Carbopol in 
52.08:20:20 & 50:30:10 % w/w ratios released the 
drug in sustained manner with integrity of 
polymeric matrix. 
The order of drug released was as follows for the 
selected formulations F4>F10 >F9>F3>F8>F7. 
Thus formulation F9 was considered to be the 
optimized one based upon its sustained release 
(70.85% within 12 hours) along with maximum 
floating by possessing its integrity.  
In-vitro drug release kinetics  
From the table- 3 it was noted that all formulations 
were exhibiting Zero order sustained release due to 
drug –polymer integrations. Formulations F4, F7 
and F10 were seen to followed the Korsmeyer- 
Peppas model whereas formulation F9 
demonstration Zero Order & Higuchi matrix kinetic 
model.  
Based on the above results it can be evident that 
formulation F9 could be considered as the 
optimized formulation from this study which was 
further confirmed for its probable mechanism of 
release by ‘n’ values of Korsmeyer–Peppas mode 
which was found to be 0.85. The ‘n’ values within 
the range of 0.45-0.85 indicated that F9 
formulation release mechanism was non –Fickian 
diffusion or anomalous diffusion. 
Drug polymer compatibility studies 
The XRD pattern of pure drug showed in the figure 
also appeared on the same location in the 
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formulations indicating there is no crystalline 
interaction and ciprofloxacin and polymers 
diffractograms showed the amorphous pattern.    
 
CONCLUSION:  
Controlled release floating capsules released  the 
drug in sustained manner  due to HPMC K4M the 
rate retarding polymer and could float at the target 
site  ( Stomach ) for more than 24 hours by 
carbopol swelling polymer. Gas generating agent 
further supports the prolong floating with short lag 
time by CO2 gas generation resulting the dosage 
unit to retain in the stomach.  Thus this could be 
beneficial in enhancing the bioavailability of the 
drug due to its absorption window at the target site. 
Henceforth the effectiveness of treatment and 
patient compliance could be improved with the 
proposed F9 ciprofloxacin floating capsule. 
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